In the Journal of American Medical Association article (4-year results), the authors concluded that after 3.8 years of follow-up among patients with non-valvular AF at elevated risk for stroke, percutaneous LAA closure met criteria for both non-inferiority and superiority, compared with warfarin, for preventing the combined outcome of stroke, systemic embolism, and cardiovascular death, as well as superiority for cardiovascular and all-cause mortality.
Holmes D R et al, Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial, Lancet, 2009;374:534-42.
Reddy V Y et al, Safety of Percutaneous Left Atrial Appendage Closure: Results from the WATCHMAN Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECT AF) Clinical Trial and the Continued Access Registry, Circulation, AHA, January 2011.
Reddy V Y et al, Percutaneous Left Atrial Appendage Closure for Stroke Prophylaxis in Patients with Atrial Fibrillation: 2.3 Year Follow-Up of the PROTECT AF Trial, Circulation, AHA, January 2013.
Reddy V Y et al, Percutaneous Left Atrial Appendage Closure vs Warfarin for Atrial Fibrillation: A Randomized Clinical Trial, The Journal of the American Medical Association, November 2014.
Watchman I: First Report of the 5-Year PROTECT-AF and Extended PREVAIL Results
Learn more about the PROTECT AF trial